Cargando…
Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature
Immune-checkpoint inhibitors (ICIs) are the most effective treatments nowadays. Nivolumab was the second ICI used for treating solid tumors with amazing results. Patients treated with Nivolumab may react differently to this treatment. Some people tolerate this treatment very well without experiencin...
Autores principales: | Pîrlog, Cristina-Florina, Paroșanu, Andreea Ioana, Slavu, Cristina Orlov, Olaru, Mihaela, Popa, Ana Maria, Iaciu, Cristian, Niță, Irina, Moțatu, Pompilia, Horia, Cotan, Manolescu, Loredana Sabina Cornelia, Nițipir, Cornelia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777769/ https://www.ncbi.nlm.nih.gov/pubmed/36547155 http://dx.doi.org/10.3390/curroncol29120741 |
Ejemplares similares
-
Restricted Mean Survival Time—Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?
por: Pîrlog, Cristina-Florina, et al.
Publicado: (2023) -
Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
por: Pirlog, Cristina-Florina, et al.
Publicado: (2022) -
Desensitization Protocol to Carboplatin: A Technical Report
por: Nitipir, Cornelia, et al.
Publicado: (2022) -
Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy
por: Parosanu, Andreea, et al.
Publicado: (2022) -
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)